Table 2.
Four hours postmaleate injection±pyruvate therapy
| Groups | BUN | PCr | NGAL mRNA | HO-1 mRNA | MCP-1 mRNA | TNF-α mRNA |
|---|---|---|---|---|---|---|
| Control | 20±1 | 0.4±0.02 | 0.02±0.01 | 0.25±0.02 | 0.07±0.04 | 0.3±0.04 |
| Maleate | 43±3 | 0.76±0.11 | 0.27±0.06 | 1.43±0.41 | 0.79±0.2 | 2.28±0.4 |
| Maleate + pyruvate | 20±3a | 0.45±0.04a | 0.04±0.02a | 2.99±0.2a | 0.12±0.03a | 0.81±0.2 |
Eight mice were injected with Na maleate (600 mg/kg). One half received Na pyruvate therapy. Four hours later, BUN, plasma creatinine (PCr), and renal cortical mRNAs were assessed. Marked protection was observed with pyruvate, which was indicated by markedly reduced or normalized BUN, PCr, and renal cortical NGAL levels. Furthermore, a pyruvate-mediated anti-inflammatory effect was observed (reduced TNF-α and MCP-1 mRNAs and increased HO-1 mRNA).
a
Statistical comparisons of maleate versus maleate+pyruvate: BUN, P<0.03; PCr, P<0.04; NGAL, P<0.02; HO-1, P<0.001; MCP-1, P<0.03; TNF-α, P<0.02.